ERBB2 and myopathy: A 45‐year‐old woman with HER2‐low MBC and normal body composition (BMI 22.9 kg/m2, visceral adipose area [VAT] 69.1 cm2) developed Trastuzumab deruxtecan (T‐DXd) myopathy.